Ironwood Pharma (IRWD) Stock Statistics & Valuation Metrics

Ironwood Pharma has a market cap or net worth of $152.99M. The enterprise value is $1.22B.

Ironwood Pharma has 161.81M shares outstanding. The number of shares has decreased by -2.65% in one year.

Ironwood Pharma’s return on equity (ROE) is 2.89 and return on invested capital (ROIC) is -258.69%.

The current PE Ratio of Ironwood Pharma is -1.77. Ironwood Pharma’s PEG ratio is <0.01.

In the last 12 months, Ironwood Pharma had revenue of $378.42M and earned $24.98M in profits. Earnings per share was -$0.03.

In the last 12 months, operating cash flow was $124.17M and capital expenditures -$353.00K, giving a free cash flow of $123.82M billion.

Ironwood Pharma pays an annual dividend of $2.29, resulting in a dividend yield of

Ironwood Pharma upcoming earnings date is May 1, 2025, TBA.

Ironwood Pharma as a current ratio of 0.84, with Debt / Equity ratio of -2.07

In the past 12 months, Ironwood Pharma has paid $74.68M in taxes.

Ironwood Pharma EV to EBITDA ratio is -2.60, with an EV/FCF ratio of 13.11.

Ironwood Pharma has $88.21M in cash and marketable securities with $614.87M in debt, giving a net cash position of $526.66M billion.

Gross margin is 76.33%, with operating margin of -213.54%, and net profit margin of -226.37%.

The average price target for Ironwood Pharma is $8.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy